In the last trading session, 3.96 million Novavax, Inc (NASDAQ:NVAX) shares changed hands as the company’s beta touched 3.06. With the company’s per share price at $8.38 changed hands at $0.39 or 4.88% during last session, the market valuation stood at $1.35B. NVAX’s last price was a discount, traded about -184.73% off its 52-week high of $23.86. The share price had its 52-week low at $3.81, which suggests the last value was 54.53% up since then. When we look at Novavax, Inc’s average trading volume, we note the 10-day average is 3.79 million shares, with the 3-month average coming to 4.31 million.
Analysts gave the Novavax, Inc (NVAX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.14. If we narrow down to specifics, the data shows that 0 out of 16 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended NVAX as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight. Novavax, Inc’s EPS for the current quarter is expected to be -0.42.
Novavax, Inc (NASDAQ:NVAX) trade information
Instantly NVAX was in green as seen at the end of in last trading. With action 2.44%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 4.23%, with the 5-day performance at 2.44% in the green. However, in the 30-day time frame, Novavax, Inc (NASDAQ:NVAX) is 2.44% up. Looking at the short shares, we see there were 39.23 million shares sold at short interest cover period of 9.02 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 61.91% from its current market value. According to analyst projections, NVAX’s forecast low is 14 with 25 as the target high. To hit the forecast high, the stock’s price needs a -198.33% plunge from its current level, while the stock would need to soar -67.06% for it to hit the projected low.
Novavax, Inc (NVAX) estimates and forecasts
Year-over-year growth is forecast to reach -26.12% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 67.7M. 4 analysts are of the opinion that Novavax, Inc’s revenue for the current quarter will be 150.3M. The company’s revenue for the corresponding quarters a year ago was 93.86M and 415.48M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -27.87%. The estimates for the next quarter sales put growth at -63.83%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 25.88%. The 2025 estimates are for Novavax, Inc earnings to increase by 81.77%, but the outlook for the next 5-year period is at 67.92% per year.
NVAX Dividends
Novavax, Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Novavax, Inc (NASDAQ:NVAX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.80% of Novavax, Inc shares while 60.19% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 65.99%. There are 60.19% institutions holding the Novavax, Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 10.0599% of the shares, roughly 14.08 million NVAX shares worth $178.19 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.4669% or 11.85 million shares worth $149.98 million as of 2024-06-30.
